Upcoming webinar: The genetics of congenital myopathies in French Canadians
The Neuromuscular Disease Network for Canada (NMD4C) and Muscular Dystrophy Canada (MDC) are pleased to invite you to a basic science webinar on July 7 at 5:00-6:30pm EST about the genetics of congenital myopathies in French Canadians. This webinar is primarily targeted at Canadian clinicians, academics and trainees with an interest in neuromuscular disease. NMD4C and MDC are providing organisational and technical support, and this is an independent clinical/academic webinar with no industry sponsorship.
If you have any questions, please email
Register HERE
Topics and speakers:
Welcome and Introduction on Congenital Myopathies in Québec
Dr. Bernard Brais (NMD4C Investigator)
Next-Generation Sequencing Approaches for the Diagnosis of Muscle Diseases
Dr. Martine Tétreault
A Novel Recessive TNNT1 Congenital Core-Rod Myopathy in French Canadians
Dr. David Pellerin
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.